Clicky

Summit Therapeutics plc(SMMT)

Description: Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.


Keywords: Medicine Disease Antibiotics Drug Discovery Dementia Summit Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Cdi Clostridioides Difficile Clostridium Difficile Infection Clostridium Difficile Drug Discovery Platform Ezutromid

Home Page: www.summittxinc.com

SMMT Technical Analysis

One Broadway
Cambridge, MA 02142
United States
Phone: 617 514 7149


Officers

Name Title
Mr. Robert W. Duggan CEO & Exec. Chairman
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA Co-CEO, Pres & Director
Dr. Urte Gayko Ph.D. Head of Regulatory Affairs, Quality Assurance & Safety and Director
Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Mr. Ankur Dhingra Chief Financial Officer
Ms. Michelle Avery Director of Investor Relations
Dr. Elaine Carla Stracker J.D., Ph.D. Head of Compliance? & Gen. Counsel
Mr. Campbell Hair Head of HR?
Dr. Anne Heatherington Head of Clinical Devel. and Quantitative Sciences
Ms. Divya Chari Head of Global Clinical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.9226
Price-to-Sales TTM: 753.9008
IPO Date: 2015-03-05
Fiscal Year End: January
Full Time Employees: 105
Back to stocks